I believe that's the last big HCV deal. Virochem shareholders got $100M cash plus 10.7M VRTX shares. VRTX stock was around 29/share at that time I believe, so that equates to about a $410M deal total when you add in the cash. I believe the Virochem compounds had completed Phase 1 trials as well at the time. I'm not saying it's going to happen of course, but look at ACHN sitting at a $90M market cap with Phase 1 PoC now for ACH-1625 (and ACH-2684 about to enter Phase 1 next year) and I think it's easy to see that there's at least the potential for some serious upside in ACHN. There are risks of course too.
It's easier to compare ACHN to the Virochem at the time of the VRTX deal than it is to compare IDIX given that IDIX has a lot more ongoing than Virochem did at the time and IDX184 is more advanced as well than I believe any of Virochem's compounds were.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.